Regeneron Pharmaceuticals | 692.8000 / +1.37% |
Date/Time | 05/27 / 22:00 |
Chg. / Chg.(%) | 9.3600 / +1.37% |
Bid | 684.5000 / 100 |
Ask | 692.9300 / 1400 |
Open | 685.7200 |
Previous Close | 683.4400 |
High | 693.8100 |
Low | 680.0000 |
Volume [USD] | 180,212,367.2577 |
Volume [Units] | 558,444 |
Price fixings | 982 |
ISIN | US75886F1075 |
Security | REGN |
Exchange | NASDAQ |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 692.8000 | ![]() |
558,444 |
IEX | 692.90 | ![]() |
30,782 |
Cboe US | 692.68 | ![]() |
19,214 |
Xetra | 643.30 | ![]() |
155 |
Frankfurt | 639.4000 | ![]() |
85 |
TradeGate | 639.700 | ![]() |
81 |
London Domes.. | 687.31 | ![]() |
47 |
Vienna Globa.. | 642.70 | ![]() |
16 |
Stuttgart | 643.800 | ![]() |
10 |
Quotrix | 630.5000 | ![]() |
7 |
gettex | 643.800 | ![]() |
4 |
Hamburg | 630.90 | ![]() |
0 |
Hannover | 630.90 | ![]() |
0 |
Düsseldorf | 641.60 | ![]() |
0 |
Berlin | 629.60 | ![]() |
0 |
München | 636.70 | ![]() |
0 |
Lang & Schwa.. | 647.40 | ![]() |
|
Mexico | 12,570.00 | ![]() |
15 |
News
- Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
03/29/2022 / 03:00 - GlobeNewswire - Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
03/26/2022 / 15:00 - GlobeNewswire - Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
03/21/2022 / 12:00 - GlobeNewswire - Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
02/28/2022 / 22:01 - GlobeNewswire - Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
02/26/2022 / 18:05 - GlobeNewswire